Michael Brennan, MD
Physical Medicine & Rehabilitation · Fairfield, CTNPI 1538117049
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,605 of the $19,026 with a category attached, or 61.0%. 34 manufacturers reported payments, led by Biodelivery Sciences International, Inc. at 24.1% of the total. Reporting peaked in 2021 at $10,240 and has fallen 97.9% since, to $216 in 2024. Among physical medicine & rehabilitation clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $42.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$5K
- Redhill Biopharma Inc.$4K
- Scilex Pharmaceuticals Inc.$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Collegium Pharmaceutical, Inc.$1K
- Purdue Pharma L.p.$1K
- plus $3K from 28 others
What the payments were for
- Consulting fees$1,0005%
- Speaking & faculty fees$11,60561%
- Food & beverage$6,32833%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biodelivery Sciences International, Inc. | 30 | $4,588 |
| Redhill Biopharma Inc. | 12 | $4,295 |
| Scilex Pharmaceuticals Inc. | 41 | $3,792 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 82 | $1,134 |
| Collegium Pharmaceutical, Inc. | 88 | $1,084 |
| Purdue Pharma L.p. | 1 | $1,000 |
| AbbVie(2 entities) | 56 | $767 |
| Pfizer | 18 | $324 |
| Upsher-smith Laboratories LLC | 15 | $264 |
| Zyla Life Sciences, Inc. | 12 | $204 |
| Amgen(2 entities) | 10 | $196 |
| Arbor Pharmaceuticals, Inc. | 9 | $174 |
| Biohaven Pharmaceuticals, Inc. | 9 | $163 |
| Lilly USA, LLC | 9 | $162 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $136 |
| Novartis | 6 | $133 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| IBSA Pharma Inc. | 4 | $73 |
| Sentynl Therapeutics, Inc. | 4 | $63 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Lundbeck LLC | 2 | $42 |
| Protega Pharmaceutials Inc | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Shionogi Inc | 2 | $30 |
| AstraZeneca | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Kaleo, Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Bioventus LLC | 1 | $14 |
| Nevro Corp. | 1 | $12 |
| USWM, LLC | 1 | $11 |
| MDD US Operations, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,026 in reported general payments places this provider in the 95th percentile of 107 physical medicine & rehabilitation providers in Connecticut.
See all physical medicine & rehabilitation providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 215 | $230,109 |
| Xtampza ErOxycodone Myristate | 115 | $118,638 |
| NucyntaTapentadol Hcl | 35 | $55,953 |
| Oxycodone Hcl | 974 | $33,593 |
| ZtlidoLidocaine | 18 | $16,442 |
| Fentanyl | 104 | $14,444 |
| Oxymorphone Hcl ErOxymorphone Hcl | 14 | $12,549 |
| MovantikNaloxegol Oxalate | 21 | $11,605 |
| Morphine Sulfate | 147 | $6,370 |
| Morphine Sulfate ErMorphine Sulfate | 163 | $6,189 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $5,119 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 128 | $4,196 |
| Hydromorphone ErHydromorphone Hcl | 17 | $3,995 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 113 | $3,846 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 17 | $3,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Purdue Pharma L.p.Oxycontin | $1,000 | $230,109215 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta | $1,084 | $174,592150 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $3,792 | $16,44218 claims |
| Redhill Biopharma Inc.Movantik | $4,295 | $11,60521 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine-Naloxone | $34 | $11,489163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 107 physical medicine & rehabilitation providers in Connecticut.
Other physical medicine & rehabilitation in Fairfield
- Elizabeth BrennanFairfield$180
- Andrew YuanFairfield$112
- Charles OdonkorOld Saybrook$81K
- Bridget WalkerHartford$41K
- Robert KrugHartford$14K
- Michael WongMilford$12K
- Daniel KlineBranford$10K
- Peter MoleyStamford$5K
- Matthew RaymondSouthington$4K
- Mitchell PrywesDanbury$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.